































Disruption in metabolic homeostasis and over 
accumulation of metabolites, cholesterol, bile acids, 
triglycerides (fat), or glucose, play causative roles in the 
development of metabolic disorders, such as, 
atherosclerosis and related heart disease, fatty liver, 
obesity, and diabetes. The NAD
+-dependent SIRT1 
deacetylase plays a critical role in maintaining 
metabolic homeostasis which affects aging so that 
SIRT1 increases life spans in most organisms, including 
mammals [1-3]. Despite extensive studies on SIRT1 
function and its beneficial metabolic effects, how the 
expression of SIRT1 is regulated under normal 
conditions and how SIRT1 levels are decreased in 
metabolic disease states remain unclear. In this review, 
we survey recent studies showing how SIRT1 
expression is regulated at the post-transcriptional level, 
focusing on microRNAs (miRs) which have recently 
emerged as important cellular regulators [4-6]. We also 
review recent studies showing that the nuclear receptor 
FXR/SHP cascade pathway which controls expression 
of miR-34a and its target SIRT1 in normal conditions 
and is dysregulated in metabolic disease states. 
 
 




























SIRT1: a key regulator in cellular metabolism 
 
Caloric restriction (CR) was shown to increase life span 
and promote survival in yeast, worms, flies, rodents and 
perhaps primates [1, 2]. SIRT1 mediates the beneficial 
metabolic effects of CR in an NAD
+-dependent manner 
by deacetylating and altering the activities of 
transcriptional factors which regulate metabolic genes 
[1, 2, 7]. SIRT1 deacetylates and activates transcript-
tional ability of metabolic regulators, such as PGC-1α, 
p53, Foxo 1, NF-κB, LXR, and FXR that are involved 
in lipid and glucose metabolism, inflammation, 
mitochondrial biogenesis, and energy balance [1, 2, 8-
12]. In addition, SIRT1 was shown to be recruited to the 
promoter of metabolic target genes and suppress their 
transcription [13, 14]. It was reported that SIRT1 is 
associated with the promoter of PPARγ, a key 
adipogenic factor, and suppresses PPARγ transcription 
by recruiting the corepressors, NcoR1 and SMRT [14]. 
SIRT1 was reported to bind to the UCP 2 gene promoter 
and inhibit its transcription in pancreatic β-cells, 
resulting in increased ATP production and insulin 
secretion [13]. SIRT1 was also shown to improve 





















cascade  pathway  that  controls  the  expression  of  miR‐34a  and  its  target  SIRT1;  and  a  FXR/SIRT1  positive  feedback
regulatory loop, which is deregulated in metabolic disease states.  The FXR/miR‐34a pathway and other miRs controlling
SIRT1 may be useful therapeutic targets for age‐related diseases, including metabolic disorders.    
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insulin action, via histone deacetylation [15]. Beneficial 
metabolic functions of SIRT1 have been demonstrated 
in studies using small molecule activators and 
transgenic mice that are null for SIRT1 or overexpress 
SIRT1 [16-20]. The natural compound resveratrol and 
the synthetic compound SRT1720 are activators of 
SIRT1 and have been shown to ameliorate insulin 
resistance, increase mitochondrial content, improve 
metabolic profiles, and increase survival in mice fed a 
high-fat diet [16-18]. Transgenic mice expressing 
SIRT1 were shown to be resistant to body weight gain 
and ameliorated insulin resistance and glucose 
intolerance in these mice compared to wild-type control 
mice [20]. Further, transgenic mice expressing moderate 
amounts of SIRT1 were also shown to protect livers 
from diet-induced metabolic damage [12, 21]. 
Consistent with these reports, in liver-specific SIRT1 
null mice challenged with a high fat diet, fatty acid 
metabolism was altered and the development of fatty 
livers and inflammatory responses were promoted [19, 
22]. Loss of function studies also showed that SIRT1 
decreases endothelial activation in hypercholesterolemic 
ApoE-/- mice without affecting endothelium-dependent 
vasodilatation [23]. All these recent studies demonstrate 
that SIRT1 is a key regulator of cellular metabolism and 
mediates beneficial metabolic effects. 
 
MicroRNAs: emerging metabolic regulators 
 
MicroRNAs (miRNAs) are small (approximately 22 nt) 
non-coding RNAs that control gene expression [4-6]. 
MiRs are transcribed from DNA by RNA polymerase II 
as hairpin precursors which are further processed to 
mature forms [4-6]. MiRs bind to the 3’-untranslated 
region (UTR) of target mRNAs and inhibit their 
expression by causing mRNA cleavage or inhibition of 
translation. Approximately 30% of all human genes are 
thought to be regulated by miRs [5, 6] and indeed, miRs 
control gene expression in diverse biological processes 
including development, differentiation, cell prolifera-
tion, and apoptosis. Recent studies have demonstrated 
crucial roles of miRNAs in the regulation of cellular 
metabolism [24-32]. MiRs are involved in lipid and 
glucose metabolism in major metabolic tissues, such as, 
liver, pancreas, adipose, and muscle as summarized in 
Table 1. Mir-122 is the most abundant miR in the liver 
and plays important roles in a wide variety of liver 
functions ranging from cholesterol metabolism, liver 
cancer, stress responses, viral infection, to circadian 
regulation of hepatic genes [24, 28, 29]. MiR-33 has 
been shown to contribute to the regulation of cholesterol 
homeostasis by targeting the cholesterol transporter 
genes, ABCA1 and ABCG1 [25, 26]. Our group 
recently reported that miR-34a targets hepatic SIRT1 
and, interestingly, expression of miR-34a was highly 
elevated and SIRT1 levels were decreased in fatty livers 
of diet-induced obese mice [30]. MiR-34a was also 
shown to suppress insulin secretion in pancreatic β-cells 
[33]. The roles of miR-375 in pancreatic islet functions, 
especially in insulin gene transcription, insulin 
secretion, and islet cell growth, are also well established 
[31, 32]. Mir-27 and miR-378 were reported to control 
adipocyte differentiation and lipid synthesis, 
respectively [34, 35]. MiR-223 was shown to regulate 
glucose uptake in cardiomyocytes and miR-696 to 
regulate mitochondria biogenesis and fatty acid 
oxidation in gastrocnemius muscle [36, 37]. In line with 
their critical functions, miRs are often underexpressed 
or overexpressed in disease states [4, 6, 24, 28, 30, 38-
40]. Recent studies have shown that restoring miRs or 
downregulating miRs using antisense miR inhibitors, 
called antagomirs, has improved transcriptional and 
biological outcomes, demonstrating that miRs are 
promising therapeutic targets [4, 24, 38]. 
 
Down-regulation of SIRT1 by microRNAs 
 
Consistent with its critical roles in diverse biological 
processes, the regulation of SIRT1 expression is fine 
tuned at multiple levels, including transcriptional, post-
transcriptional, and post-translational levels. The 
general regulation of SIRT1 activity and expression has 
been thoroughly reviewed in excellent articles [1-3, 41] 
and, therefore, this review focuses on the regulation of 
SIRT1 expression by miRs (Table 2). MiR-34a was first 
identified as a posttranscriptional regulator of SIRT1 in 
the regulation of apoptosis under cellular genotoxic 
stress in human colon cancer HCT116 cells [42]. MiR-
34a binds to the 3’ UTR of SIRT1 mRNA in a partial 
complementary manner and represses its translation but 
does not affect mRNA degradation [30, 42]. Our group 
further reported that miR-34a targets hepatic SIRT1 in 
the regulation of cellular metabolism in human 
hepatoma HpeG2 cells and in mouse liver in vivo using 
adenoviral-mediated overexpression of miR-34a [30]. 
Remarkably, we observed that miR-34a levels are 
highly elevated and SIRT1 protein levels are 
substantially decreased in the fatty livers of both diet-
induced obese mice and the leptin-deficient ob/ob mice 
[30]. These findings are in line with recent studies 
showing that miR-34a is the most elevated miR in livers 
exhibiting nonalcoholic steatohepatitis, a spectrum of 
nonalcoholic fatty liver diseases in humans [39]. Other 
miRs also target SIRT1. In response to nutritional 
availability, miR-132 was shown to downregulate 
SIRT1, resulting in activation of inflammatory 
pathways in adipose tissues [43]. MiR-199a was 
identified as a negative regulator of SIRT1 and HIF1a, a 
key mediator of hypoxia [44]. Low oxygen tension 
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myocytes and in porcine heart and this reduction is 
required for upregulation of its targets, HIF-1a and 
SIRT1 in response to decreased oxygen [44]. 
Interestingly, a recent study showed that SIRT1 

















































stem cells (ESCs) than in differentiated tissues and 
that miRNAs, miR-181a and b, miR-9, miR-204, miR-
199b, and miR-135, post-transcriptionally down-
regulate SIRT1 during mouse ESC differentiation and 
maintain low levels of SIRT1 expression in 




















































MicroRNA  Direct targets 
[putative]  Functions in Metabolism (references)  Tissues  
(cultured cells) 
miR-33  ABCA1, 




miR-34a  SIRT1  Lipid metabolism, promotes fatty liver (30) 
miR-370  Cpt1a   Fatty acid and triglyceride biosynthesis (29) 
miR-122  CAT-1 
ADAM17 
Hepatic lipid metabolism (24, 29) 
Circadian gene expression (28) 




miR-124a  Foxa2  Intracellular signaling in pancreatic β-cell (27) 
miR-375  MTPN  Regulates catecholamine release 
Inhibits insulin secretion (31, 32) 
miR-27a  [PPARγ, 
C/EBPα] 
Inhibits adipocyte formation,  
Down-regulated during adipogenic differentiation 
(34)  (Adipocytes, 3T3-
L1, ST2) 
miR-378/378*  [Ribosomal 
proteins] 
Upregulates adipocyte differentiation and lipid 
synthesis (35) 




miR-696  [PGC1α] 
Muscle metabolism, mitochondria biogenesis and 
fatty acid oxidation (37) 
Table 2. MicroRNAs targeting SIRT1 
 
MicroRNA  Sequences of microRNAs   Size 
(nt)  Biological functions (references) 
miR-34a  5’-uggcagugucuuagcugguugu-3’ 22 
Hepatic lipid metabolism (30) 
Islet β-cell exocytosis (33)  
Cell apoptosis (42) 
miR-132  5’-uaacagucuacagccauggucg-3’ 22  Stress-induced chemokine production (43) 
miR-199a  5’-cccaguguucagacuaccuguuc-3’ 25  Hypoxia preconditioning (44) 
 
   



























A novel FXR/SHP/miR-34a pathway controlling 
SIRT1 levels 
 
The nuclear bile acid receptor, Farnesoid X Receptor 
(FXR), plays an important role in maintaining lipid and 
glucose levels by regulating expression of numerous 
metabolic genes mainly in the liver and intestine [46]. 
Consistent with its important metabolic functions, 
disruption of the FXR gene in transgenic mice was 
associated with metabolic diseases, including 
hypercholesterolemia, cholesterol gallstone disease, 
fatty liver, and type 2 diabetes [46-49]. Activation of 
FXR in diabetic obese mice improved metabolic 
outcomes by reducing serum glucose and lipid levels 
[50]. Although both FXR and SIRT1 have been shown 
to be critical for hepatic metabolism and activation of 
both proteins improves metabolic outcomes in diet-
induced obese mice [17, 18, 46, 47, 50], it was 
unknown whether the expression and activity of these 
two proteins are coordinately regulated. In recent 
studies, we found that FXR positively regulates hepatic 
SIRT1 expression by inhibiting expression of miR-34a 
[30]. As shown in Figure 1, under normal conditions, 
miR-34a levels are down-regulated by a nuclear 
receptor cascade pathway involving FXR and orphan 
nuclear receptor and metabolic repressor, Small 
Heterodimer Partner (SHP) [51, 52]. Upon induction by 




























ter and suppresses its transcription by inhibiting the 
promoter occupancy of p53, the key activator of the 
miR-34a gene [53]. Subsequently, inhibition of miR-
34a contributes to increased expression of SIRT1. This 
FXR/SHP pathway was also shown to play a crucial 
role in the regulation of hepatic bile acid synthesis by 
inhibiting the rate-limiting bile acid synthetic enzyme 
CYP7A1 [51, 52] and to suppress fatty liver formation 
by inhibiting the key lipogenic activator SREBP-1c 
[54]. Our group has identified molecular mechanisms 
by which SHP inhibits its target genes by coordinately 
recruiting chromatin modifying repressive cofactors, 
including HDACs, G9a metyltransferase, and Brm-
containing Swi/Snf remodeling complex [55-57]. 
Consistent with these previous findings, we observed 
recruitment of HDACs to the miR-34a promoter in 
mouse liver after treatment with the synthetic FXR 
agonist, GW4064 (not shown). In contrast, in fatty 
livers of obese mice, the FXR/SHP pathway is 
dysregulated such that miR-34a levels are highly 
elevated, which contributes to reduced SIRT1 levels 
[30]. Interestingly, activation of FXR signaling in obese 
mice by daily treatment with GW4064 for 5 days or by 
hepatic expression of FXR using adenoviral delivery 
decreased miR-34a levels and restored SIRT1 levels 
[30]. Consistent with a critical role for FXR in 
positively controlling SIRT1 through the inhibition of 
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null mice [30]. Our findings suggest an intriguing link 
among FXR activation, decreased miR-34a levels, 
increased SIRT1 levels, and beneficial metabolic 
outcomes. 
 
A positively interacting FXR/SIRT1 regulatory loop 
 
In the FXR/SHP/miR-34a pathway, FXR positively 
regulates hepatic SIRT1 levels by inhibiting 
transcription of the miR-34a gene. These findings, 
along with previous studies showing the p53/miR-
34a/SIRT1 feedback loop [42, 58], suggest intriguing 
regulatory loops controlling SIRT1 expression (Figure 
2). In the short regulatory loop, SIRT1 positively auto-
regulates its own expression by deacetylating p53 and 
histones at the miR-34a promoter, resulting in 
suppression of miR-34a [9, 30, 42, 53, 58]. In the long 
regulatory loop, SIRT1-mediated deacetylation of FXR 
increases FXR’s transactivation ability by increasing 
binding of the FXR/RXR heterodimer to DNA resulting 
in induction of SHP and repression of miR-34a 
expression [11, 30]. We observed that FXR acetylation 































deacetylase under normal conditions, and remarkably, 
FXR acetylation levels are highly elevated in fatty livers 
of obese mice [11]. Interestingly, treatment daily with 
the SIRT1 activator resveratrol for 1 week or 
adenoviral-mediated hepatic expression of SIRT1 
substantially reduced FXR acetylation with beneficial 
metabolic effects [11]. These results are consistent with 
the idea that the transactivation activity of FXR is low 
in obese mice due to highly elevated FXR acetylation, 
which contributes to increased expression of miR-34a. 
Subsequently, elevated miR- 34a suppresses expression 
of SIRT1, which then further decreases FXR activity, 
resulting in a vicious FXR/miR-34a/SIRT1 regulatory 
loop in metabolic disease states. In addition to 
deacetylation of FXR, SIRT1 has been implicated as a 
positive regulator of the expression and activity of FXR. 
During fasting, PGC-1α was shown to increase 
expression of the FXR gene and function as a 
coactivator of FXR [59]. Since SIRT1 deacetylates and 
increases PGC-1α activity [8], SIRT1 should increase 
FXR expression and activity by enhancing PGC-1α 
activity. All these recent studies strongly suggest that 
the expression and activity of these two proteins are 
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Because of SIRT1’s anti-aging properties and its 
beneficial effects on a wide range of age-related disease 
[1-3, 21], it has been intensively studied. SIRT1 levels 
were reported to be decreased in liver, muscle, and 
adipose tissues of diet-induced obese mice in vivo as 
well as in cultured cell models of insulin resistance [15, 
30, 60], but the underlying mechanisms remain unclear. 
The discovery of the FXR/miR-34a pathway controlling 
SIRT1 levels provides a partial explanation since 
elevated miR-34a levels in obese mice contribute to 
decreased SIRT1 levels [30]. Based on these findings, 
together with the development of effective inhibitors of 
miRs, the antagomirs [4, 24, 38], it will be interesting to 
see whether the reduction of elevated miR-34a in fatty 
livers of obesity improves transcriptional profiles of 
metabolic genes and metabolic outcomes. Also, it will 
be important to understand how the FXR/SIRT1 
regulatory network is dysregulated in metabolic disease 
states which likely involves altered cellular kinase 
signaling pathways that post-transcriptionally affect 
SIRT1 and FXR levels and activities. Development of 
drugs that target the FXR/miR-34a pathway and other 
miRs controlling SIRT1 expression may lead to novel 
therapeutic options for treating age-related metabolic 
disease including fatty liver, obesity and type II diabetes. 
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